
|Videos|July 7, 2023
The AMPECT Trial: Nab-sirolimus in PEComa
Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
4
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
5








































